Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul-Dec;23(10):987-1003.
doi: 10.1080/14712598.2023.2245326. Epub 2023 Oct 5.

Oncolytic virotherapies for pediatric tumors

Evan G Gross  1 , Mohammad A Hamo  1 , Dagoberto Estevez-Ordonez  2 , Nicholas Mb Laskay  2 , Travis J Atchley  2 , James M Johnston  2   3 , James M Markert  2
Affiliations
Review

Oncolytic virotherapies for pediatric tumors

Evan G Gross et al. Expert Opin Biol Ther. 2023 Jul-Dec.

Abstract

Introduction: Many pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which may be associated with considerable long-term morbidity. The emergence of oncolytic virotherapy (OVT) may provide an alternative or adjuvant treatment for pediatric oncology patients.

Areas covered: We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). For each virus, we discuss the mechanism of tumor-specific replication and cytotoxicity as well as key findings of preclinical and clinical studies.

Expert opinion: Substantial progress has been made in the past 10 years regarding the clinical use of OVT. From our review, OVT has favorable safety profiles compared to chemotherapy and radiation treatment. However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

Keywords: Adenovirus; herpes simplex virus; measles virus; oncolytic virus; pediatric tumors; poliovirus; reovirus; vaccinia virus.

PubMed Disclaimer

Conflict of interest statement

Research reported in this publication was supported in part by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R25NS079188 (awarded to D Estevez-Ordonez). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This study was also completed while D Estevez-Ordonez was a Cornwall Clinical Scholar supported by UAB. James M is a board member, equity holding member (< 8%), and receives royalties from Aettis, Inc. This company holds frozen oncolytic viral stocks. Mustang Bio Tech is licensing the IP of C134 an oncolytic viral therapy. J Markert is blinded to the conditions of licensing and any potential receipts he could be awarded for the C134 clinical trials. J Markert is a 25% shareholder for Treovir, Inc. LLC, a privately held Small Business Innovation Research LLC developing G207 oncolytic viral therapy now in clinical trial for pediatric patients. He does not have a pediatric practice personally. J Markert, along with UAB, hold IP in In8bio, a privately held corporation developing gamma-delta T cells for anti-glioma therapy. Merck has agreed to provide industry grant support by providing Keytruda (pembrolizumab) and funding for a pending clinical trial of M032 oncolytic virotherapy. J Markert receives the occasional invitation to present findings to other academic medical institutions (e.g., UT Southwestern, MD Anderson, Memorial Sloan Kettering, Vanderbilt) for which he may receive honoraria. J Markert received structured buyout payments from Amgen, Inc., a publicly traded company which holds a patent for oncolytic virotherapy, (for the sale of Catherex, Inc. which no longer exists.) Final payment was received in March/April, 2021. J Markert served as external consultant and received compensation for work completed in 2020 as well as travel reimbursement from Imugene Limited. J Markert is the principal investigator for NIH grants R01CA222903 and R01CA217179. He is also a co-investigator for NIH grant R01FD05379-01. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Figures

Figure 1.
Figure 1.
General characteristics of oncolytic viruses. (a) Examples of proposed mechanisms for oncolytic virus tumor-specific cytotoxicity. (b) Intravenous versus in situ administration of oncolytic virus. (c) Proposed pathway of virus-mediated tumor-specific oncolysis. (d) Role of carrier cells in oncolytic virus delivery to tumor. Abbreviations: Rb, retinoblastoma tumor suppressor; PAMP, pathogen-associated molecular pattern; DAMP, damage-associated molecular pattern; NK cells, natural killer cells. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654 - DOI - PubMed
    1. Zhou X, Liao X, Zhang B, et al. Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol. 2016;5(2):289–294. doi:10.3892/mco.2016.936 - DOI - PMC - PubMed
    1. Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–2211. doi:10.1056/NEJMra0804577 - DOI - PMC - PubMed
    1. Plant-Fox AS, O’Halloran K, Goldman S. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Curr Probl Cancer. 2021;45(4):100777. doi:10.1016/j.currproblcancer.2021.100777 - DOI - PubMed
    1. Foreman PM, Friedman GK, Cassady KA, Markert JM. Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics. 2017;14(2):333–344. doi:10.1007/s13311-017-0516-0 - DOI - PMC - PubMed

Publication types

LinkOut - more resources